Synthetic lethality on drug discovery: an update on cancer therapy

References

• Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med. 2003 Jun;348(23):2339–2347.
   PubMed Web of Science ®Google Scholar
• Hanson S, Thorpe G, Winstanley L, et al. Omega-3, omega-6 and total dietary polyunsaturated fat on cancer incidence: systematic review and meta-analysis of randomised trials. Br J Cancer. 2020;29:1.
   Google Scholar
• Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006 Sep;25(43):5864–5874.
   PubMed Web of Science ®Google Scholar
• Tutt A, Bertwistle D, Valentine J, et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. Embo J. 2001 Sep;20(17):4704–4716.
   PubMed Web of Science ®Google Scholar
• Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell. 2001 Feb;7(2):263–272.
   PubMed Web of Science ®Google Scholar
• Moynahan ME, Chiu JW, Koller BH, et al. Brca1 controls homology-directed DNA repair. Mol Cell. 1999 Oct;4(4):511–518.
   PubMed Web of Science ®Google Scholar
• Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer. 2004 Sep;4(9):665–676.
   PubMed Web of Science ®Google Scholar
• Tutt ANJ, Lord CJ, McCabe N, et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol. 2005;70:139–148.
   PubMedGoogle Scholar
• Dhanjal KJ, Radhakrishnan N, Sundar D, et al. Identifying synthetic lethal targets using CRISPR/Cas9 system. Methods. 2017 D;131:66–73.
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.[erratum appears in Nature. 2007 May 17;447(7142):346]. Nature. 2005;434(7035):913–917.
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005 Apr;434(7035):917–921.
   PubMed Web of Science ®Google Scholar
• Boulton S, Kyle S, Durkacz BW, et al. Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Carcinogenesis. 1999 Feb;20(2):199–203.
   PubMed Web of Science ®Google Scholar
• Saffhill R, Ockey CH. Strand breaks arising from the repair of the 5-bromodeoxyuridine-substituted template and methyl methanesulphonate-induced lesions can explain the formation of sister chromatid exchanges. Chromosoma. 1985;92(3):218–224.
   PubMed Web of Science ®Google Scholar
• Schultz N, Lopez E, Saleh-Gohari N, et al. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res. 2003 Sep;31(17):4959–4964.
   PubMed Web of Science ®Google Scholar
• McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006 Aug;66(16):8109–8115.
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol. 2008 Aug;8(4):363–369.
   PubMed Web of Science ®Google Scholar
• Hartwell LH, Szankasi P, Roberts CJ, et al. Integrating genetic approaches into the discovery of anticancer drugs. Science. 1997 Nov;278(5340):1064–1068.
   PubMed Web of Science ®Google Scholar
• Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005;5(9):689–698.
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017 Mar;355(6330):1152–1158.
   PubMed Web of Science ®Google Scholar
• Gagné J-P, Hendzel MJ, Droit A, et al. The expanding role of poly(ADP-ribose) metabolism: current challenges and new perspectives. Curr Opin Cell Biol. 2006 Apr;18(2):145–151.
   PubMed Web of Science ®Google Scholar
• Amé J-C, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays. 2004 Aug;26(8):882–893.
   PubMed Web of Science ®Google Scholar
• Otto H, Reche PA, Bazan F, et al. In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs). BMC Genomics. 2005 Oct;6(1):139.
   PubMed Web of Science ®Google Scholar
• Dantzer F, Amé J-C, Schreiber V, et al. Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair. Methods Enzymol. 2006;409:493–510.
   PubMed Web of Science ®Google Scholar
• Zaremba T, Curtin NJ. PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med Chem. 2007 Sep;7(5):515–523.
   PubMed Web of Science ®Google Scholar
• Plummer ER, Calvert H. Targeting poly(ADP-ribose) polymerase: a two-armed strategy for cancer therapy. Clin Cancer Res. 2007 Nov;13(21):6252–6256.
   PubMed Web of Science ®Google Scholar
• Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 2004 Oct;4(10):814–819.
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS, Tutt ANJ. Triple negative tumours: a critical review. Histopathology. 2008 Jan;52(1):108–118.
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J, Schwartzberg L, Danso MA, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2014 Dec;32(34):3840–3847.
   PubMed Web of Science ®Google Scholar
• Soucek L, Whitfield J, Martins CP, et al. Modelling Myc inhibition as a cancer therapy. Nature. 2008 Oct;455(7213):679–683.
   PubMed Web of Science ®Google Scholar
• Shachaf CM, Kopelman AM, Arvanitis C, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature. 2004 Oct;431(7012):1112–1117.
   PubMed Web of Science ®Google Scholar
• Rottmann S, Wang Y, Nasoff M, et al. A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3β/FBW7 loss of function. Proc Natl Acad Sci U S A. 2005 Oct;102(42):15195–15200.
   PubMed Web of Science ®Google Scholar
• Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011 Aug;478(7370):524–528.
   PubMed Web of Science ®Google Scholar
• Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011 Sep;146(6):904–917.
   PubMed Web of Science ®Google Scholar
• Liu L, Ulbrich J, Müller J, et al. Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature. 2012 Mar;483(7391):608–612.
   PubMed Web of Science ®Google Scholar
• Hsu TYT, Simon LM, Neill NJ, et al. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature. 2015 Sep;525(7569):384–388.
   PubMed Web of Science ®Google Scholar
• Kessler JD, Kahle KT, Sun T, et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 2012 Jan;335(6066):348–353.
   PubMed Web of Science ®Google Scholar
• Aguirre AJ, Hahn WC. Synthetic lethal vulnerabilities in KRAS -mutant cancers. Cold Spring Harb Perspect Med. 2018 Aug;8(8):a031518.
   PubMed Web of Science ®Google Scholar
• Kopetz S, McDonough SL, Morris VK, et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAFmutant metastatic colorectal cancer (SWOG 1406). J Clin Oncol. 2017 Feb;35(4):520–520.
   Google Scholar
• Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019 Jun;381(4):317–327.
   PubMed Web of Science ®Google Scholar
• Christ TN. Olaparib: A tale of two dosage forms. Semin Oncol. 2019 Feb 1;46(1):100–101.
   PubMed Web of Science ®Google Scholar
• Shuaishi G. & Luhua L., Synthetic lethality in drug development: the dawn is coming, Future Med. Chem. 2018;10(18):2129–2132.
   Google Scholar
• Wang Z, Dai W-P, Zang Y-S. Complete response with fluorouracil and irinotecan with a BRAFV600E and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report. Onco Targets Ther. 2019 Jan;12:443–447.
   PubMed Web of Science ®Google Scholar
• Pan R, Ruvolo V, Mu H, et al. Synthetic lethality of combined Bcl-2 inhibition and p53 activation in AML: mechanisms and superior antileukemic Efficacy. Cancer Cell. 2017 Dec;32(6):748–760.e6.
   PubMed Web of Science ®Google Scholar
• Turner NC, Telli ML, Rugo HS, et al. A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO). Clin Cancer Res. 2019 May;1; 25(9):2717–2724.
   Web of Science ®Google Scholar
• Jonas BA. Novel drug combination unleashes apoptosis in AML. Sci Transl Med. 2018 Jan;10(422):eaar7509.
   Google Scholar
• Branzei D, Foiani M. Maintaining genome stability at the replication fork. Nat Rev Mol Cell Biol. 2010 Mar;11(3):208–219.
   PubMed Web of Science ®Google Scholar
• Wallace K, Goble S, Isaacson J, et al. Comment on:“cost-effectiveness of niraparib versus routine surveillance, olaparib and rucaparib for the maintenance treatment of patients with ovarian cancer in the United States. PharmacoEconomics. 2019 Aug;1;37(8):1065–1067.
   Web of Science ®Google Scholar
• Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003 May;3(5):421–429.
   PubMed Web of Science ®Google Scholar
• Wang Q, Fan S, Eastman A, et al. UCN-01: A potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst. 1996 Jul;88(14):956–965.
   PubMedGoogle Scholar
• Sargazi S, Saravani R, Reza JZ, et al. Novel poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, AZD2461, down-regulates VEGF and induces apoptosis in prostate cancer cells. Iran Biomed J. 2019 Sep;23(5):312.
   PubMedGoogle Scholar
• Reilly SW, Puentes LN, Schmitz A, et al. Synthesis and evaluation of an AZD2461 [18F] PET probe in non-human primates reveals the PARP-1 inhibitor to be non-blood-brain barrier penetrant. Bioorg Chem. 2019 Mar;1(83):242–249.
   Google Scholar
• Kortmansky J, Shah MA, Kaubisch A, et al. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with fluorouracil in patients with advanced solid tumors. J Clin Oncol. 2005;23(9):1875–1884.
   PubMed Web of Science ®Google Scholar
• Wang Y, Engels IHKnee DA, et al, Synthetic Lethal Targeting Of Myc by Activation Of The Dr5 Death Receptor Pathway, Cancer Cell. 2004 May;5(5):501–12.
   Google Scholar
• Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer. 2008 Feb 12;98(3):523–528.
   PubMed Web of Science ®Google Scholar
• Shaheen M, Allen C, Nickoloff JA, et al. Synthetic lethality: exploiting the addiction of cancer to DNA repair. Blood. 2011 Jun;117(23):6074–6082.
   PubMed Web of Science ®Google Scholar
• Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res. 2010 Jan;16(2):376–383.
   PubMed Web of Science ®Google Scholar
• Dai Y, Yu C, Singh V, et al. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res. 2001 Jul;61(13):5106–5115.
   PubMed Web of Science ®Google Scholar
• Dai Y, Chen S, Shah R, et al. Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo. Blood. 2011 Feb;117(6):1947–1957.
   PubMed Web of Science ®Google Scholar
• Anderson VE, Walton MI, Eve PD, et al. CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors. Cancer Res. 2011 Jan;71(2):463–472.
   PubMed Web of Science ®Google Scholar
• Hickson I, Zhao Y, Richardson CJ, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 2004 Dec;64(24):9152–9159.
   PubMed Web of Science ®Google Scholar
• Nishida H, Tatewaki N, Nakajima Y, et al. Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response. Nucleic Acids Res. 2009 Jul;37(17):5678–5689.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Thomas HD, Batey MA, et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res. 2006 May;66(10):5354–5362.
   PubMed Web of Science ®Google Scholar
• Dupré A, Boyer-Chatenet L, Sattleret RM. et al. A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex,”. Nat Chem Biol. 2008;4(2):119–125.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhong S, Zhu X, et al. Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair. Cancer Res. 2008 May;68(9):3169–3177.
   PubMed Web of Science ®Google Scholar
• Bapat A, Fishel ML, Kelley MR. Going ape as an approach to cancer therapeutics. Antioxid Redox Signaling. 2009 Mar 01;11(3):651–667.
   PubMed Web of Science ®Google Scholar
• Wilson DM, Simeonov A. Small molecule inhibitors of DNA repair nuclease activities of APE1. Cell Mol Life Sci. 2010 Nov;67(21):3621–3631.
   PubMed Web of Science ®Google Scholar
• Kaina B, Margison GP, Christmann M. Targeting O 6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cell Mol Life Sci. 2010 Nov;67(21):3663–3681.
   PubMed Web of Science ®Google Scholar
• Jacquemont C, Taniguchi T. Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res. 2007 Aug;67(15):7395–7405.
   PubMed Web of Science ®Google Scholar
• Heinzel A, Marhold M, Mayer P, et al. Synthetic lethality guiding selection of drug combinations in ovarian cancer. PLoS One. 2019 Jan;14(1):e0210859.
   PubMed Web of Science ®Google Scholar
• Zhao D. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature. 2017 Feb;542(7642):484–488.
   PubMed Web of Science ®Google Scholar
• Wang T, Yu H, Huges NW, et al. Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic ras. Cell. 2017 Feb;168(5):890–903.e15.
   PubMed Web of Science ®Google Scholar
• Weidle UH, Maisel D, Eick D. Synthetic lethality-based targets for discovery of new cancer therapeutics. Cancer Genomics Proteomics. 2011;8(4):159–171.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Lord CJ, Ashworth A. DAISY: picking synthetic lethals from cancer genomes. Cancer Cell. 2014 Sep;26(3):306–308.
   PubMed Web of Science ®Google Scholar
• Jorgensen TJ. Enhancing radiosensitivity: targeting the DNA repair pathways. Cancer Biol Ther. 2009 Apr 15;8(8):665–670. Landes Bioscience.
   PubMed Web of Science ®Google Scholar
• Hammel M, Yu Y, Mahaney BL, et al. Ku and DNA-dependent protein kinase dynamic conformations and assembly regulate DNA binding and the initial non-homologous end joining complex. J Biol Chem. 2010;285(2):1414–1423.
   PubMed Web of Science ®Google Scholar
• Sibanda BL, Chirgadze DY, Blundell TL. Crystal structure of DNA-PKcs reveals a large open-ring cradle comprised of HEAT repeats. Nature. 2010 Jan;463(7277):118–121.
   PubMed Web of Science ®Google Scholar
• Edwards SL, Brough R, Christopher J, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008 Feb;451(7182):1111–1115.
   PubMed Web of Science ®Google Scholar
• Muller FL, Aquilanti EA, DePinho RA. Collateral lethality: a new THERAPEUTIC STRATEGY IN Oncology. Trends Cancer. 2015 Nov;1(3):161–173.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee S, Nandi S. Synthetic lethality in DNA repair network: A novel avenue in targeted cancer therapy and combination therapeutics. IUBMB Life. 2017 Dec;69(12):929–937.
   PubMed Web of Science ®Google Scholar
• Meyers RM, Bryan JG, McFarland JM, et al. Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells. Nat Genet. 2017 Dec;49(12):1779–1784.
   PubMed Web of Science ®Google Scholar
• Sweeney SM. AACR project GENIE: powering precision medicine through an international consortium. Cancer Discov. 2017 Aug;7(8):818–831.
   PubMed Web of Science ®Google Scholar
• Tsherniak A, Vazquez F, Montgomery PG, et al. Defining a cancer dependency map. Cell. 2017 Jul;170(3):564–576.e16.
   PubMed Web of Science ®Google Scholar
• Kabadi A, McDonnell E, Frank CL, et al. Applications of functional genomics for drug discovery. Slas Discovery. 2020;6:2472555220902092.
   Google Scholar
• Edwards, R Brough SL, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008 Feb;451(7182):1111–1115.
   PubMed Web of Science ®Google Scholar
• Beijersbergen RL, Wessels LFA, Bernards R. Synthetic lethality in cancer therapeutics. Annu Rev Cancer Biol. 2017 Mar;1(1):141–161.
   Google Scholar
• Kamal A, Shaik TB, Malik MS. Embracing synthetic lethality of novel anticancer therapies. Expert Opin Drug Discov. 2015 Oct;3;10(10):1119–1132.
   PubMed Web of Science ®Google Scholar